Results 231 to 240 of about 189,595 (350)

Oral Anticoagulant Therapy

, 1994
Jack Hirsh
openalex   +2 more sources

Evaluation of Risk Factors for Stroke/Embolism and of Complications Due to Anticoagulant Therapy in Atrial Fibrillation [PDF]

, 2001
Cornelius Wehinger, Claudia Stöllberger, Thomas Länger, Barbara Schneider, Josef Finsterer   +4 more
openalex   +1 more source

Use of glucagon‐like peptide‐1 receptor agonists in patients with left ventricular assist devices

ESC Heart Failure, EarlyView.
Key question: does GLP1‐RA therapy improve heart transplantation rates and clinical outcomes in patients with LVADs? Key findings: in this propensity score‐matched cohort study of 1068 LVAD recipients, GLP1‐RA use was associated with higher heart transplantation rates (18.9% vs.
Ramzi Ibrahim, Hoang Nhat, Mahmoud Abdelnabi, Beani Forst, Mohamed Allam, Xuan Ci Mee, Ghee Kheng Lim, George Bcharah, Timothy Barry, Juan Farina, Chadi Ayoub, Reza Arsanjani, Kwan Lee   +12 more
wiley   +1 more source

The risk factors of liver cirrhosis complicated with portal vein thrombosis and the efficacy and safety of anticoagulant therapy: a meta analysis. [PDF]

Thromb J
Zhang L, Wang X, Ming P, Ma LN, Ma W, Ding XC.   +5 more
europepmc   +1 more source

Galectin‐3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE‐TIMI 58

ESC Heart Failure, EarlyView.
Abstract Background Galectin‐3 (Gal‐3) is a circulating biomarker of fibrosis, with higher levels being associated with an increased risk of progression of heart failure and kidney disease. Patients with type 2 diabetes mellitus (T2DM) are at increased risk of both.
Paul M. Haller, Stephen D. Wiviott, David D. Berg, Petr Jarolim, Erica L. Goodrich, Deepak L. Bhatt, Ingrid Gause‐Nilsson, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Itamar Raz, Marc S. Sabatine, David A. Morrow   +12 more
wiley   +1 more source

Validation, Content Validity, and Reliability of the Spanish SE-OAM Questionnaire: Assessing Nursing Self-Efficacy in Oral Anticoagulant Therapy Management. [PDF]

Clin Pract
de-Moya-Romero JR, Valera-Lloris R, Chover-Sierra E, Fernández-Puerta L, Caballero-Bonafé A, Martínez-Sabater A.   +5 more
europepmc   +1 more source

Cardioimmunologic response patterns after an acute heart failure event: Design and first results of AHF‐ImmunoCS

ESC Heart Failure, EarlyView.
Abstract Aims We have previously shown that patients who develop heart‐reactive antibodies (HRAs) de novo after a heart failure (HF) hospitalization are at increased risk of adverse outcomes, lending weight to the hypothesis that B cells may play a pivotal role in HF progression.
Niklas Beyersdorf, Boshra Afshar, Dora Pelin, Maximilian Bauser, Elisa Kaiser, Janna Lamers, Jannika Pätkau, Mairin Heil, Dennis Göpfert, Hanna Hepp, Wafaa Al Hassan, Thomas Kerkau, Fabian Kerwagen, Roland Jahns, Valerie Boivin‐Jahns, Stefan Frantz, Gustavo Ramos, Ulrich Hofmann, Stefan Störk, Caroline Morbach   +19 more
wiley   +1 more source

Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
ABSTRACT Aims Anaemia is common in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and associated with poor clinical outcomes. While renin–angiotensin system blockers reduce haemoglobin, little is known about the effect of mineralocorticoid receptor antagonists on haemoglobin and in patients with anaemia.
Misato Chimura, Mingming Yang, Alasdair D. Henderson, Pardeep S. Jhund, Kieran F. Docherty, Brian L. Claggett, Akshay S. Desai, Gerasimos Filippatos, Grzegorz Gajos, Katharina Mueller, Andrea Glasauer, Katja Rohwedder, Prabhakar Viswanathan, Carolyn S.P. Lam, Naoki Sato, Michele Senni, Adriaan A. Voors, Faiez Zannad, Mehmet B. Yilmaz, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray, on behalf of the FINEARTS‐HF Committees and Investigators   +23 more
wiley   +1 more source

Two causes of COVID‐19‐related myocardial injury‐associated cardiogenic shock: Myocarditis and microvascular thrombosis

ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai, Hirohiko Aikawa, Yoshiaki Morita, Keiko Ohta‐Ogo, Teruo Noguchi   +4 more
wiley   +1 more source

Cardiac resynchronization therapy for enabling guideline‐directed medical therapy optimization in heart failure

European Journal of Heart Failure, EarlyView.
Cardiac resynchronization therapy (CRT) as an enabler for guideline‐directed medical therapy (GDMT) in the Swedish Heart Failure Registry (SwedeHF). The figure summarizes the selection of the study population, changes in GDMTs and loop diuretic use/doses from baseline to 1.5‐year follow‐up in patients receiving versus not receiving CRT, and reports the
Daniela Tomasoni, Lina Benson, Paolo Gatti, Alessandro Villaschi, Charlotta Ljungman, Marco Metra, Raffaele Scorza, Frieder Braunschweig, Michael Melin, Giuseppe Rosano, Michael Böhm, Javed Butler, William T. Abraham, Wilfried Mullens, Fredrik Gadler, Cecilia Linde, Lars H. Lund, Gianluigi Savarese   +17 more
wiley   +1 more source